FDA authorizes Physio-Control to market LIFEPAK 20e defibrillator
The U.S. Food and Drug Administration has granted clearance to Physio-Control, Inc. for the commercialization of LIFEPAK 20e defibrillator/monitor in the United States. The device is an enhancement of the LIFEPAK 20. The new features include a stronger (Lithium-ion) battery and an on-screen fuel gauge. The novel version, also, is designed to facilitate easy transportation. This will help the hospitals to meet the standards set by Joint Commission for Accreditation of Healthcare Organizations to ensure the availability of resuscitation services in all the areas.
- Europe initiates implants of Cognis, Teligen
- FDA approves market launch of Boston Scientific’s DES
- FDA nod to Endologix’s IntuiTrak⢠Delivery System
- FDA approval to Covidien’s ANDA
